VERACYTE, INC.
No enriched coverage for $VCYT in the last 7 days.
Febbo Phillip G. (Chief Scientific & Med Officer) sold 13,110 shares of VERACYTE, INC. (VCYT) at an average of $43.05 ($42.89–$43.66, $0.56M total) across 2 trades on 2026-09-04 under a Rule 10b5-1 trading plan.
VERACYTE, INC. (VCYT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Veracyte Announces Second Quarter 2026 Financial Results Grew total revenue to $150.3 million and testing revenue to $145.7 million, representing increases of 15% and 19% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCIS
Meridian Small Cap Growth Fund’s Q2 2026 investor letter cited Veracyte, Inc. (NASDAQ:VCYT) after the company’s earnings beat and an upward revision to full-year guidance. The article notes VCYT closed at $55.71 on July 29, 2026, with Q1 2026 revenue of $139.1 million (21% YoY) and mentions Decipher and Afirma performance plus upcoming launches.
Recent VCYT coverage spans insider activity, earnings and financial news.
In the last 30 days, VCYT insiders filed 7 SEC Form 4 transactions — no purchases and 7 sales ($942K). The most active reporter was McGuire Annie, EVP, General Counsel, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Insider sale may signal reduced confidence or portfolio rebalancing, potentially pressuring the stock short-term.
Guidance raise plus strong Q2 growth and cash generation suggests improving demand and execution, likely supporting upward estimate revisions.
The article frames a positive earnings-and-guidance catalyst tied to sustained test volume growth and improved workflow outcomes.
A disclosed trim with no new fundamentals; likely low incremental trading value.
The filing is primarily corporate-governance/compensation related via equity plan amendments, which can affect dilution expectations and near-term sentiment.
alphai scores every news story that mentions VCYT with an AI model for sentiment and relevance, and aggregates insider trades from VERACYTE, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Febbo Phillip G. (Chief Scientific & Med Officer) sold 13,110 shares of VERACYTE, INC. (VCYT) at an average of $43.05 ($42.89–$43.66, $0.56M total) across 2 trades on 2026-09-04 under a Rule 10b5-1 trading plan.
1 min readVERACYTE, INC. (VCYT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Veracyte Announces Second Quarter 2026 Financial Results Grew total revenue to $150.3 million and testing revenue to $145.7 million, representing increases of 15% and 19% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCIS
6 min readMeridian Small Cap Growth Fund’s Q2 2026 investor letter cited Veracyte, Inc. (NASDAQ:VCYT) after the company’s earnings beat and an upward revision to full-year guidance. The article notes VCYT closed at $55.71 on July 29, 2026, with Q1 2026 revenue of $139.1 million (21% YoY) and mentions Decipher and Afirma performance plus upcoming launches.
4 min readArk Invest, led by Cathie Wood, sold shares from its ARKK ETF during a market rally tied to a U.S.-Iran peace agreement. Reported trades include selling 66,259 Palantir shares (~$8.9M at $134.71), 6,904 TSM shares (~$3.0M at $441.40), and 46,783 Amazon shares (~$11.5M at $246.02). The article also cites other sales (e.g., 10X Genomics, Veracyte, Shopify).
5 min readVERACYTE, INC. (VCYT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex1018-k06x10x2026.htm EX-10.1 Document Exhibit 10.1 VERACYTE, INC. 2023 EQUITY INCENTIVE PLAN, AS AMENDED (ADOPTED BY THE BOARD OF DIRECTORS ON APRIL 12, 2023, AS AMENDED JUNE 12, 2024, JUNE 17, 2025 AND JUNE 10, 2026) 1. PURPOSE. The purpose of this Plan is to provide
4 min readMcGuire Annie (EVP, General Counsel) sold 1,776 shares of VERACYTE, INC. (VCYT) at $50.12 on 2026-06-04 under a Rule 10b5-1 trading plan.
2 min readMcGuire Annie (EVP, General Counsel) sold 1,400 shares of VERACYTE, INC. (VCYT) at $49.31 on 2026-06-04 under a Rule 10b5-1 trading plan.
2 min readChambers Rebecca (Chief Financial Officer) sold 1,961 shares of VERACYTE, INC. (VCYT) at $50.09 on 2026-06-04 under a Rule 10b5-1 trading plan.
2 min readChambers Rebecca (Chief Financial Officer) sold 1,600 shares of VERACYTE, INC. (VCYT) at $49.28 on 2026-06-04 under a Rule 10b5-1 trading plan.
2 min readStapley Marc (Chief Executive Officer) sold 138,051 shares of VERACYTE, INC. (VCYT) at $50.12 ($6.92M total) on 2026-06-04 under a Rule 10b5-1 trading plan.
2 min read
